Coffman J D, Rasmussen H M
Clin Pharmacol Ther. 1984 Sep;36(3):369-73. doi: 10.1038/clpt.1984.189.
To determine whether thromboxane A2 may be of pathogenetic importance in Raynaud's phenomenon, finger hemodynamic and clinical responses to dazoxiben, a thromboxane synthetase inhibitor, were studied in 25 subjects. Thirteen subjects had idiopathic Raynaud's disease and 12 subjects had secondary Raynaud's disease. A double-blind, 2-week crossover study design was used. Dazoxiben dose was 100 mg four times a day. Total fingertip blood flow (FBF) by venous occlusion plethysmography, fingertip capillary flow (FCF) by radioisotope disappearance rate, and finger systolic blood pressure (FSP) were measured in a 28.3 degree and a 20 degree room at the end of each period. Subjects kept diaries of vasospastic attacks. For the 25 subjects and the two subgroups, dazoxiben did not improve total FBF, FCF, or FSP. Subjects with idiopathic Raynaud's disease had a small decrease in the number of vasospastic attacks and an increase in percentage of attack-free days on dazoxiben, but in an overall evaluation by the subjects in both subgroups, dazoxiben did not improve symptoms. It is concluded that thromboxane is not of pathogenetic importance in Raynaud's phenomenon and that thromboxane synthesis inhibition is not of therapeutic benefit.
为确定血栓素A2在雷诺现象的发病机制中是否具有重要意义，我们对25名受试者使用血栓素合成酶抑制剂达唑氧苯，研究了手指血流动力学及临床反应。其中13名受试者患有特发性雷诺病，12名受试者患有继发性雷诺病。采用双盲、为期2周的交叉研究设计。达唑氧苯剂量为每日4次，每次100毫克。在每个研究阶段结束时，于室温28.3摄氏度和20摄氏度的环境下，通过静脉阻断体积描记法测量指尖总血流量（FBF），通过放射性同位素消失率测量指尖毛细血管血流量（FCF），并测量手指收缩压（FSP）。受试者记录血管痉挛发作情况。对于这25名受试者及两个亚组，达唑氧苯并未改善指尖总血流量、指尖毛细血管血流量或手指收缩压。患有特发性雷诺病的受试者使用达唑氧苯后，血管痉挛发作次数略有减少，无发作天数的百分比有所增加，但在两个亚组受试者的总体评估中，达唑氧苯并未改善症状。研究得出结论，血栓素在雷诺现象的发病机制中不具有重要意义，抑制血栓素合成并无治疗益处。
